Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
gptkb:drug |
| gptkbp:approvedBy |
gptkb:FDA
1990 |
| gptkbp:ATCCode |
P01CX03
|
| gptkbp:brand |
gptkb:Ornidyl
gptkb:Vaniqa |
| gptkbp:CASNumber |
66389-74-0
|
| gptkbp:chemicalFormula |
C12H19F3N2O2
|
| gptkbp:developedBy |
cancer treatment (not effective)
|
| gptkbp:discoveredBy |
gptkb:Cyrus_Bacchi
|
| gptkbp:eliminationHalfLife |
3 hours (IV)
|
| gptkbp:excretion |
urine
|
| https://www.w3.org/2000/01/rdf-schema#label |
eflornithine
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
ornithine decarboxylase inhibitor
|
| gptkbp:meltingPoint |
~150°C
|
| gptkbp:metabolism |
minimal
|
| gptkbp:molecularWeight |
296.29 g/mol
|
| gptkbp:otherName |
gptkb:DFMO
gptkb:difluoromethylornithine |
| gptkbp:routeOfAdministration |
topical
intravenous |
| gptkbp:sideEffect |
gptkb:anemia
diarrhea hearing loss seizures |
| gptkbp:usedFor |
treatment of African trypanosomiasis
treatment of facial hirsutism |
| gptkbp:WHOModelListOfEssentialMedicines |
yes
|
| gptkbp:bfsParent |
gptkb:Trypanosomiasis
|
| gptkbp:bfsLayer |
5
|